Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 66.5%

Neg 0% Neu 0% Pos 66.5%

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.